JP5522195B2 - 栄養組成物および消化管機能低下予防・改善用組成物 - Google Patents
栄養組成物および消化管機能低下予防・改善用組成物 Download PDFInfo
- Publication number
- JP5522195B2 JP5522195B2 JP2012101794A JP2012101794A JP5522195B2 JP 5522195 B2 JP5522195 B2 JP 5522195B2 JP 2012101794 A JP2012101794 A JP 2012101794A JP 2012101794 A JP2012101794 A JP 2012101794A JP 5522195 B2 JP5522195 B2 JP 5522195B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- composition
- administration
- preventing
- inosinic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 87
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 53
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims description 19
- 230000006866 deterioration Effects 0.000 title claims description 15
- 239000007788 liquid Substances 0.000 claims abstract description 40
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 31
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 239000002773 nucleotide Substances 0.000 claims abstract description 17
- 230000006872 improvement Effects 0.000 claims abstract description 13
- 235000015097 nutrients Nutrition 0.000 claims description 60
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 claims description 35
- GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 claims description 34
- 235000013902 inosinic acid Nutrition 0.000 claims description 34
- AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical compound [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 claims description 33
- 235000013928 guanylic acid Nutrition 0.000 claims description 33
- 239000004245 inosinic acid Substances 0.000 claims description 33
- 229940028843 inosinic acid Drugs 0.000 claims description 33
- 239000004226 guanylic acid Substances 0.000 claims description 32
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical group C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 31
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims description 30
- 229950006790 adenosine phosphate Drugs 0.000 claims description 30
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 claims description 30
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 claims description 30
- 229930183912 Cytidylic acid Natural products 0.000 claims description 29
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 claims description 29
- FOGRQMPFHUHIGU-UHFFFAOYSA-N Uridylic acid Natural products OC1C(OP(O)(O)=O)C(CO)OC1N1C(=O)NC(=O)C=C1 FOGRQMPFHUHIGU-UHFFFAOYSA-N 0.000 claims description 29
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 claims description 29
- DCTLYFZHFGENCW-UUOKFMHZSA-N 5'-xanthylic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 DCTLYFZHFGENCW-UUOKFMHZSA-N 0.000 claims description 22
- 206010065713 Gastric Fistula Diseases 0.000 claims description 12
- 230000035764 nutrition Effects 0.000 claims description 12
- 208000008081 Intestinal Fistula Diseases 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 10
- 210000002784 stomach Anatomy 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 230000007160 gastrointestinal dysfunction Effects 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 230000015556 catabolic process Effects 0.000 claims description 4
- 238000006731 degradation reaction Methods 0.000 claims description 4
- 210000001198 duodenum Anatomy 0.000 claims description 3
- 210000001630 jejunum Anatomy 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract description 36
- 235000013922 glutamic acid Nutrition 0.000 abstract description 36
- 239000004220 glutamic acid Substances 0.000 abstract description 36
- 230000007661 gastrointestinal function Effects 0.000 abstract description 15
- 208000021302 gastroesophageal reflux disease Diseases 0.000 abstract description 13
- 235000015872 dietary supplement Nutrition 0.000 abstract description 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 46
- 229960002989 glutamic acid Drugs 0.000 description 35
- 238000000034 method Methods 0.000 description 18
- 235000019583 umami taste Nutrition 0.000 description 18
- 239000000126 substance Substances 0.000 description 15
- 230000006870 function Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000004615 ingredient Substances 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 235000019640 taste Nutrition 0.000 description 12
- 229940049906 glutamate Drugs 0.000 description 11
- 229930195712 glutamate Natural products 0.000 description 11
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 9
- 235000013923 monosodium glutamate Nutrition 0.000 description 9
- 230000001079 digestive effect Effects 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229940073490 sodium glutamate Drugs 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- AANLCWYVVNBGEE-IDIVVRGQSA-L Disodium inosinate Chemical compound [Na+].[Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 AANLCWYVVNBGEE-IDIVVRGQSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000013890 disodium inosinate Nutrition 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- PVBRXXAAPNGWGE-LGVAUZIVSA-L disodium 5'-guanylate Chemical compound [Na+].[Na+].C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP([O-])([O-])=O)[C@@H](O)[C@H]1O PVBRXXAAPNGWGE-LGVAUZIVSA-L 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 230000036397 gastrointestinal physiology Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- IRJCBFDCFXCWGO-UHFFFAOYSA-N Ibotenic acid Chemical compound OC(=O)C(N)C1=CC(=O)NO1 IRJCBFDCFXCWGO-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 238000012313 Kruskal-Wallis test Methods 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035669 Pneumonia aspiration Diseases 0.000 description 2
- 201000009807 aspiration pneumonia Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KHWCHTKSEGGWEX-RRKCRQDMSA-N 2'-deoxyadenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KHWCHTKSEGGWEX-RRKCRQDMSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003504 Aspiration Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010017877 Gastrointestinal fistula Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001562081 Ikeda Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- VBOQYPQEPHKASR-VKHMYHEASA-N L-homocysteic acid Chemical compound OC(=O)[C@@H](N)CCS(O)(=O)=O VBOQYPQEPHKASR-VKHMYHEASA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000019647 acidic taste Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000010434 protein-losing enteropathy Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- FKKZRDGVPKGOKL-UFBCLZHVSA-M sodium 2-[(2S,3S,4R,5R)-3,4-dihydroxy-5-(1-methyl-2-methylsulfanyl-6-oxopurin-9-yl)oxolan-2-yl]-2-hydroxyacetate Chemical compound CN1C(C=2N=CN([C@H]3[C@H](O)[C@H](O)[C@@H](C(O)C(=O)[O-])O3)C2N=C1SC)=O.[Na+] FKKZRDGVPKGOKL-UFBCLZHVSA-M 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- -1 tricominate Chemical compound 0.000 description 1
- 235000019607 umami taste sensations Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
(1)グルタミン酸、5’−ヌクレオチドおよびそれらの塩から選ばれる少なくとも1種を含有し、かつグルタミン酸のみを含む場合その投与時の含量が遊離グルタミン酸として0.0013〜1.3w/v%であることを特徴とする栄養組成物。
(2)用時において液状である、(1)に記載の栄養組成物。
(3)前記の5’−ヌクレオチドが、アデニル酸、イノシン酸、グアニル酸、シチジル酸、ウリジル酸および/またはキサンチル酸である、(1)または(2)に記載の栄養組成物。
(4)アデニル酸、イノシン酸、グアニル酸、シチジル酸およびウリジル酸を同時に含有しない(1)〜(3)のいずれかに記載の栄養組成物。
(5)アデニル酸、イノシン酸、グアニル酸、シチジル酸、ウリジル酸、キサンチル酸およびそれらの塩の合計含量が遊離酸として0.0035〜0.41w/v%である(1)〜(4)のいずれかに記載の栄養組成物。
(6)消化管機能低下を予防および/または改善するためのものである、(1)〜(5)のいずれかに記載の栄養組成物。
(7)下痢発症および/または胃食道逆流を抑制させるためのものである(1)〜(6)のいずれかに記載の栄養組成物。
(8)胃ろうまたは腸ろうから投与されるものである、(1)〜(7)のいずれかに記載の栄養組成物。
(9)グルタミン酸、5’−ヌクレオチドおよびそれらの塩から選ばれる少なくとも1種を含有し、かつグルタミン酸のみを含む場合その投与時の含量が遊離グルタミン酸として0.0013〜1.3w/v%であることを特徴とする、消化管機能低下予防・改善用組成物。
(10)用時において液状である、(9)に記載の消化管機能低下予防・改善用組成物。
(11)前記の5’−ヌクレオチドが、アデニル酸、イノシン酸、グアニル酸、シチジル酸、ウリジル酸および/またはキサンチル酸である、(9)または(10)に記載の消化管機能低下予防・改善用組成物。
(12)イノシン酸、アデニル酸、グアニル酸、シチジル酸およびウリジル酸を同時に含有しない(9)〜(11)のいずれかに記載の消化管機能低下予防・改善用組成物。
(13)アデニル酸、イノシン酸、グアニル酸、シチジル酸、ウリジル酸、キサンチル酸およびそれらの塩の合計含量が遊離酸として0.0035〜0.41w/v%である(9)〜(12)のいずれかに記載の消化管機能低下予防・改善用組成物。
(14)低下した消化管機能を予防および/または改善するためのものである(9)〜(13)のいずれかに記載の消化管機能低下予防・改善用組成物。
(15)下痢発症および/または胃食道逆流を抑制させるためのものである(9)〜(14)のいずれかに記載の消化管機能低下予防・改善用組成物。
(16)液状栄養剤の投与に先立って投与するためのものである(9)〜(15)のいずれかに記載の消化管機能低下予防・改善用組成物。
(17)胃ろうまたは腸ろうから投与されるものである、(9)〜(16)のいずれかに記載の消化管機能低下予防・改善用組成物。
(19)液状で投与することを特徴とする、(18)に記載の方法。
(20)前記の5’−ヌクレオチドが、アデニル酸、イノシン酸、グアニル酸、シチジル酸、ウリジル酸および/またはキサンチル酸である、(18)または(19)に記載の方法。
(21)前記組成物がイノシン酸、アデニル酸、グアニル酸、シチジル酸およびウリジル酸を同時に含有しないことを特徴とする、(18)〜(20)のいずれかに記載の方法。
(22)前記組成物に含まれるアデニル酸、イノシン酸、グアニル酸、シチジル酸、ウリジル酸、キサンチル酸およびそれらの塩の合計含量が遊離酸として0.0035〜0.41w/v%であることを特徴とする、(18)〜(21)のいずれかに記載の方法。
(23)低下した消化管機能を予防および/または改善することを特徴とする、(18)〜(22)のいずれかに記載の方法。
(24)下痢発症および/または胃食道逆流を抑制することを特徴とする、(18)〜(23)のいずれかに記載の方法。
(25)液状栄養剤の投与に先立って投与することを特徴とする、(18)〜(24)のいずれかに記載の方法。
(26)胃ろうまたは腸ろうから投与することを特徴とする、(18)〜(25)のいずれかに記載の方法。
(27)グルタミン酸、5’−ヌクレオチドおよびそれらの塩から選ばれる少なくとも1種を含有し、かつグルタミン酸のみを含む場合その投与時の含量が遊離グルタミン酸として0.0013〜1.3w/v%であることを特徴とする消化管機能低下予防・改善用組成物を製造するためのグルタミン酸、5’−ヌクレオチドおよびそれらの塩の使用。
(28)前記の5’−ヌクレオチドが、アデニル酸、イノシン酸、グアニル酸、シチジル酸、ウリジル酸および/またはキサンチル酸である、(27)に記載の使用。
(29)前記組成物がイノシン酸、アデニル酸、グアニル酸、シチジル酸およびウリジル酸を同時に含有しないことを特徴とする、(27)または(28)に記載の使用。
(30)前記組成物に含まれるアデニル酸、イノシン酸、グアニル酸、シチジル酸、ウリジル酸、キサンチル酸およびそれらの塩の合計含量が遊離酸として0.0035〜0.41w/v%であることを特徴とする、(27)〜(29)のいずれかに記載の使用。
(31)前記組成物が低下した消化管機能を予防および/または改善するためのものである、(27)〜(30)のいずれかに記載の使用。
(32)前期組成物が下痢発症および/または胃食道逆流を抑制させるためのものである、(27)〜(31)のいずれかに記載の使用。
(33)前記組成物が液状栄養剤の投与に先立って投与するためのものである、(27)〜(32)のいずれかに記載の使用。
(34)前記組成物が胃ろうまたは腸ろうから投与されるものである、(27)〜(33)のいずれかに記載の使用。
(35)グルタミン酸、5’−ヌクレオチドおよびそれらの塩から選ばれる少なくとも1種を含有し、かつグルタミン酸のみを含む場合その投与時の含量が遊離グルタミン酸として0.0013〜1.3w/v%であることを特徴とする組成物、および該組成物の消化管機能低下予防・改善への使用に関する説明を記載した記載物を含む商業的パッケージ。
方法
常法に従い、ペントバルビタール麻酔下において雄性ラット(体重270g前後)の胃に成分栄養剤投与用のカテーテルを挿入する手術を施し、1週間の術後回復期間を設けた。飼育は通常のラット用飼料と水道水を与え、自由に摂取させた。回復確認後、3晩絶食させ消化管機能の低下を引き起こした。これは外科手術患者の手術前日、当日、翌日の絶食のスケジュールを模倣した。
試験当日、ラットを3群に分類し1匹ごとに観察用ケージに移し、以下に示す成分栄養剤の投与による下痢発症を観察した。まず、表1に示す組成を有する成分栄養剤1袋(80g)を300ccの水に溶解し、1kcal/ccとなるように調製したものを成分栄養剤1とした。成分栄養剤1を投与した群を対照として、さらにグルタミン酸ナトリウム(MSG)を1.0w/v%(遊離グルタミン酸として0.88w/v%)添加した成分栄養剤2を投与した群、塩化ナトリウム0.35w/v%を添加した成分栄養剤3を投与した群の3群を比較検討した。各試験成分栄養剤は胃に挿入したカテーテルを通じ電動ポンプを使用して投与した。10:30AMより投与開始し7mL/hrで1時間ごとに4回間欠投与した。各試験成分栄養剤はラット1匹あたり計28mL投与した。投与開始から翌朝10:30AMまで便状を観察し、症状の重篤度により1.正常便または便無し、2.軟便(形状保持)、3.泥状便(形状無し)、4.水様便の4段階にランク付けした。
図1に示す通り、無添加群では12例中12例でランク4の水様便が観察された。一方、グルタミン酸ナトリウム添加群では13例中4例でランク1の正常便または便無し、1例でランク2の軟便、2例でランク3の泥状便が観察された。また塩化ナトリウム添加群では11例中1例でランク1、6例でランク3が観察された。クラスカル・ワーリスの検定を行ったところ、グルタミン酸ナトリウム添加群に有意な改善効果が認められた(p < 0.05)。
方法
方法は実施例1に準じた。実施例1と同様の成分栄養剤1を投与した群を対照として、さらにグルタミン酸ナトリウム(MSG)を0.50w/v%(遊離グルタミン酸として0.44w/v%)添加した成分栄養剤4を投与した群、イノシン酸ナトリウム(IMP)を0.20w/v%(遊離イノシン酸として0.17w/v%)添加した成分栄養剤5を投与した群の3群を比較検討した。各試験成分栄養剤は胃に挿入したカテーテルを通じ電動ポンプを使用して投与した。実験法は実施例1と同様に行った。
図2に示す通り、無添加群では12例中11例でランク4の水様便が観察された。グルタミン酸ナトリウム添加群では13例中1例でランク1の正常便または便無し、1例でランク2の軟便、2例でランク3の泥状便が観察された。ところがイノシン酸ナトリウム添加群では11例中4例でランク1、1例でランク2、1例でランク3が観察された。クラスカル・ワーリスの検定を行ったところ、イノシン酸ナトリウム添加群に有意な改善効果が認められた(p < 0.05)。
方法
方法は実施例1に準じた。別表に示す組成を有する成分栄養剤1を投与した群を対象として、さらにグアニル酸ナトリウム(GMP)を0.04w/v%(遊離グアニル酸として0.036w/v%)添加した成分栄養剤6を投与した群、0.20w/v%(遊離グアニル酸として0.18w/v%)添加した成分栄養剤7を投与した群の3群を比較検討した。各試験成分栄養剤は胃に挿入したカテーテルを通じ電動ポンプを使用して投与した。実験法は実施例1と同様に行った。
図3に示す通り、無添加群では14例中13例でランク4の水様便が、1例でランク2の軟便が観察された。グアニル酸ナトリウム0.04w/v%添加群では13例中3例でランク1の正常便または便無し、1例でランク2の軟便、9例でランク4の水様便が観察された。グアニル酸ナトリウム0.20w/v%添加群でも13例中3例でランク1の正常便または便無し、1例でランク2の軟便、9例でランク4の水様便が観察され、添加による下痢症状の改善効果が認められたと考えられる。
Claims (14)
- 5’−ヌクレオチドまたはその塩を含有し、鼻腔チューブ、胃ろうまたは腸ろうより、胃、十二指腸または空腸に投与されるものであり、液状栄養剤の投与に伴う下痢を予防および/または改善するためのものであることを特徴とする栄養組成物。
- 使用時において液状である、請求項1に記載の栄養組成物。
- 前記の5’−ヌクレオチドが、アデニル酸、イノシン酸、グアニル酸、シチジル酸、ウリジル酸および/またはキサンチル酸である、請求項1または2に記載の栄養組成物。
- アデニル酸、イノシン酸、グアニル酸、シチジル酸およびウリジル酸を同時に含有しない請求項1〜3のいずれか1項に記載の栄養組成物。
- アデニル酸、イノシン酸、グアニル酸、シチジル酸、ウリジル酸、キサンチル酸およびそれらの塩の合計含量が遊離酸として0.0035〜0.41w/v%である請求項1〜4のいずれか1項に記載の栄養組成物。
- 下痢発症を抑制させるためのものである請求項1〜5のいずれか1項に記載の栄養組成物。
- 胃ろうまたは腸ろうから投与されるものである、請求項1〜6のいずれか1項に記載の栄養組成物。
- 5’−ヌクレオチドまたはその塩を含有し、胃ろうまたは腸ろうから投与されるものであることを特徴とする、消化管機能低下予防・改善用組成物であって、消化管機能低下予防・改善が液状栄養剤の投与に伴う下痢の予防および/または改善である消化管機能低下予防・改善用組成物。
- 用時において液状である、請求項8に記載の消化管機能低下予防・改善用組成物。
- 前記の5’−ヌクレオチドが、アデニル酸、イノシン酸、グアニル酸、シチジル酸、ウリジル酸および/またはキサンチル酸である、請求項8または9に記載の消化管機能低下予防・改善用組成物。
- イノシン酸、アデニル酸、グアニル酸、シチジル酸およびウリジル酸を同時に含有しない請求項8〜10のいずれか1項に記載の消化管機能低下予防・改善用組成物。
- アデニル酸、イノシン酸、グアニル酸、シチジル酸、ウリジル酸、キサンチル酸およびそれらの塩の合計含量が遊離酸として0.0035〜0.41w/v%である請求項8〜11のいずれか1項に記載の消化管機能低下予防・改善用組成物。
- 下痢発症を抑制させるためのものである請求項8〜12のいずれか1項に記載の消化管機能低下予防・改善用組成物。
- 液状栄養剤の投与に先立って投与するためのものである請求項8〜13のいずれか1項に記載の消化管機能低下予防・改善用組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012101794A JP5522195B2 (ja) | 2004-06-28 | 2012-04-26 | 栄養組成物および消化管機能低下予防・改善用組成物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004189515 | 2004-06-28 | ||
JP2004189515 | 2004-06-28 | ||
JP2012101794A JP5522195B2 (ja) | 2004-06-28 | 2012-04-26 | 栄養組成物および消化管機能低下予防・改善用組成物 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006528774A Division JP5092400B2 (ja) | 2004-06-28 | 2005-06-23 | 栄養組成物および消化管機能低下予防・改善用組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012167108A JP2012167108A (ja) | 2012-09-06 |
JP5522195B2 true JP5522195B2 (ja) | 2014-06-18 |
Family
ID=35781908
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006528774A Expired - Fee Related JP5092400B2 (ja) | 2004-06-28 | 2005-06-23 | 栄養組成物および消化管機能低下予防・改善用組成物 |
JP2012101794A Expired - Fee Related JP5522195B2 (ja) | 2004-06-28 | 2012-04-26 | 栄養組成物および消化管機能低下予防・改善用組成物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006528774A Expired - Fee Related JP5092400B2 (ja) | 2004-06-28 | 2005-06-23 | 栄養組成物および消化管機能低下予防・改善用組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US7993668B2 (ja) |
EP (2) | EP1767201B8 (ja) |
JP (2) | JP5092400B2 (ja) |
KR (1) | KR101133944B1 (ja) |
AT (1) | ATE509623T1 (ja) |
WO (1) | WO2006001492A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4124260B2 (ja) * | 2004-09-17 | 2008-07-23 | 味の素株式会社 | 機能性消化管障害予防・改善剤及び食品 |
WO2008010527A1 (fr) * | 2006-07-18 | 2008-01-24 | Ajinomoto Co., Inc. | Composition laxative |
WO2008010472A1 (fr) * | 2006-07-18 | 2008-01-24 | Ajinomoto Co., Inc. | Composition pour nutrition entérale totale |
WO2009113594A1 (ja) * | 2008-03-11 | 2009-09-17 | 味の素株式会社 | 機能性消化管障害予防・改善剤および食品 |
JP2011084536A (ja) * | 2009-10-19 | 2011-04-28 | En Otsuka Pharmaceutical Co Ltd | 経腸栄養剤 |
CA2796936A1 (en) * | 2010-04-26 | 2011-11-10 | Nestec S.A. | Nutritional compositions and methods for weaning from parenteral nutrition to enteral nutrition |
HUE052368T2 (hu) * | 2012-10-02 | 2021-04-28 | Oil Dri Corp Of America | Agyag termék és annak alkalmazásai |
WO2014062683A1 (en) * | 2012-10-15 | 2014-04-24 | University Of Florida Research Foundation, Inc. | Materials and methods for prevention and treatment of diarrhea and inflammation in the gastrointestinal tract |
JPWO2014061808A1 (ja) * | 2012-10-19 | 2016-09-05 | Eaファーマ株式会社 | 胃ろう栄養患者用栄養組成物 |
US20140170259A1 (en) * | 2012-12-14 | 2014-06-19 | Mead Johnson Nutrition Company | Nutritional composition for promoting satiety |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US304805A (en) * | 1884-09-09 | Dinner-tray | ||
US301437A (en) * | 1884-07-01 | calveet egebton | ||
US3156569A (en) * | 1962-02-01 | 1964-11-10 | Pfizer & Co C | Seasoning composition and method of enhancing the flavor of foods containing a glutamic acid salt |
US3821471A (en) * | 1971-03-15 | 1974-06-28 | Cbs Inc | Apparatus for reproducing quadraphonic sound |
FR2193590B1 (ja) * | 1972-07-27 | 1975-10-17 | Philagro Sa | |
US3832471A (en) * | 1972-08-24 | 1974-08-27 | Liggett & Myers Inc | Method of feeding cats thawed frozen fish flavored with 5{40 -nucleotides |
US4176201A (en) * | 1977-11-25 | 1979-11-27 | Macandrews And Forbes Company | Sweetening composition |
SU1761098A1 (ru) * | 1990-05-24 | 1992-09-15 | Украинская сельскохозяйственная академия | Способ выращивани новорожденных тел т |
JPH06303918A (ja) * | 1993-04-23 | 1994-11-01 | Smith Kline Biichiyamu Nippon Zenyaku Kk | 豚と鶏の飼料添加用組成物 |
JPH07330583A (ja) * | 1994-06-03 | 1995-12-19 | Terumo Corp | 遊離型グルタミン酸を含有する液状製剤 |
GB9701374D0 (en) * | 1997-01-23 | 1997-03-12 | Univ Liverpool | Purinergic agonists and antagonists |
BR0016021A (pt) * | 1999-12-22 | 2003-07-15 | Inspire Pharmaceuticals Inc | Processo de tratamento de doenças do trato gastrointestinal com agonistas do receptor purinérgico |
JP2001233776A (ja) * | 2000-02-25 | 2001-08-28 | Yamasa Shoyu Co Ltd | 学習・記憶能低下改善剤およびその用途 |
GB0009056D0 (en) * | 2000-04-12 | 2000-05-31 | Nestle Sa | Composition comprising free amino acids |
CA2437380A1 (en) * | 2001-02-05 | 2002-08-15 | Michael Albert Kamm | A treatment of oesophageal motility disorders and gastro-oesophageal reflux disease |
JP3860110B2 (ja) | 2002-12-09 | 2006-12-20 | 日機装株式会社 | カーボンナノファイバーの黒鉛化処理装置 |
JP4287763B2 (ja) * | 2003-03-31 | 2009-07-01 | 株式会社興人 | 母豚母乳中の5’−ヌクレオチド含有量を増加させる方法、母豚用飼料添加物及び母豚用飼料 |
-
2005
- 2005-06-23 KR KR1020077001885A patent/KR101133944B1/ko not_active IP Right Cessation
- 2005-06-23 EP EP05755641A patent/EP1767201B8/en not_active Not-in-force
- 2005-06-23 JP JP2006528774A patent/JP5092400B2/ja not_active Expired - Fee Related
- 2005-06-23 EP EP10011493.3A patent/EP2305240B1/en not_active Not-in-force
- 2005-06-23 AT AT05755641T patent/ATE509623T1/de not_active IP Right Cessation
- 2005-06-23 WO PCT/JP2005/012010 patent/WO2006001492A1/ja active Application Filing
-
2006
- 2006-12-28 US US11/617,137 patent/US7993668B2/en not_active Expired - Fee Related
-
2012
- 2012-04-26 JP JP2012101794A patent/JP5522195B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JPWO2006001492A1 (ja) | 2008-04-17 |
EP1767201B8 (en) | 2012-02-29 |
EP2305240B1 (en) | 2014-12-03 |
WO2006001492A1 (ja) | 2006-01-05 |
ATE509623T1 (de) | 2011-06-15 |
EP1767201B1 (en) | 2011-05-18 |
JP5092400B2 (ja) | 2012-12-05 |
EP1767201A1 (en) | 2007-03-28 |
EP2305240A1 (en) | 2011-04-06 |
KR20070039083A (ko) | 2007-04-11 |
JP2012167108A (ja) | 2012-09-06 |
US7993668B2 (en) | 2011-08-09 |
KR101133944B1 (ko) | 2012-04-13 |
US20070218109A1 (en) | 2007-09-20 |
EP1767201A4 (en) | 2008-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5522195B2 (ja) | 栄養組成物および消化管機能低下予防・改善用組成物 | |
US10306909B2 (en) | Amino acid based diet with improved taste | |
ES2523198T3 (es) | Composición nutricional enteral líquida alta en energía | |
JP2003530411A (ja) | 遊離アミノ酸含有組成物 | |
JP2006503105A (ja) | ロイシンに富んだ栄養的組成物 | |
JP5085541B2 (ja) | 疲労軽減剤 | |
JP2013100336A (ja) | 癌患者に対する長期栄養供給 | |
ES2314485T3 (es) | Composiciones que comprenden acido pantotenico o derivados del mismo y su uso para estimular el apetito. | |
JP7434155B2 (ja) | オートファジーの誘導のためにオートファジー誘導因子と高タンパク質との組み合わせを使用する組成物及び方法 | |
JPWO2004019928A1 (ja) | 肝疾患治療剤 | |
WO2009072869A1 (en) | High energy liquid enteral nutritional composition | |
CA3011633A1 (en) | Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate | |
JPWO2005123058A1 (ja) | 老化防止剤 | |
SE501114C2 (sv) | Magnesiumtillsats för livsmedel, foder, läkemedel | |
JP3908513B2 (ja) | 肝機能改善剤 | |
Parks et al. | Nutritional management of the infant with necrotizing enterocolitis | |
RU2335927C2 (ru) | Обогащенные лейцином питательные композиции | |
CARSON | Homocystinuria: Trial Treatment of a 5-Year Ola Severely Retarded Child With a Natural Diet Low in Methionine | |
JP4721684B2 (ja) | ダイフラクトースアンハイドライド含有経口組成物 | |
Stegink et al. | Sugar-amino acid complexes in parenteral alimentation | |
JP4111429B2 (ja) | 骨粗鬆症予防剤又は治療剤 | |
JP4111428B2 (ja) | 骨粗鬆症予防剤又は治療剤 | |
JP5412830B2 (ja) | 便通改善用組成物 | |
Valentine et al. | Nutritional support in children | |
JP2019058140A (ja) | 栄養組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120522 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131015 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131212 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140311 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140324 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5522195 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |